Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To estimate the generalisability of treatment effects observed in a randomised trial of hip fracture surgery implants, to a broader population of people undergoing hip surgery in the United Kingdom. STUDY DESIGN AND SETTING: In 2018, the WHiTE-3 trial (n=958) demonstrated that a modular hemiarthroplasty implant conferred no additional benefit over the traditional monoblock implant for quality of life and length of hospital stay. We compared and weighted the trial sample against two target populations: WHiTE-cohort (n=2,457) and UK-National Hip Fracture Database (NHFD, n=190,894), and re-estimate expected treatment effects for the target populations. RESULTS: Despite differences in baseline characteristics of the trial sample and target populations, the re-estimated treatment effects were comparable. For quality of life, the differences between the trial estimate and WHiTE-cohort and NHFD estimates were 0.01 points on the EuroQol (EQ5D). For length of stay, the difference between the trial estimate and WHiTE-cohort was 0.50 days; and the difference between the trial estimate and NHFD estimate was -0.47 days. CONCLUSION: This generalisability analysis of the WHiTE-3 trial found that the inferences from the trial can be generalised to the group of individuals in the UK NHFD and the WHiTE-cohort who met the inclusion criteria for WHiTE-3.

Original publication

DOI

10.1016/j.jclinepi.2020.11.016

Type

Journal article

Journal

J clin epidemiol

Publication Date

02/12/2020

Keywords

External validity, generalizability, hip fracture, surgery